Learn how intravaginal cooling offers symptom relief for vulvovaginal candidiasis (VVC) and reduces immune response pathology ...

Vaginal infections are more common problem among women. In the US alone, an estimated 75 percent of women are reported to ...

Geode Capital Management LLC increased its stake in SCYNEXIS, Inc. (NASDAQ:SCYX – Free Report) by 10.0% during the 3rd ...

June 20, 2024 — Women who have their ovaries removed before menopause, particularly before the age of 40, have reduced white matter integrity in multiple regions of the brain later in life, a ...

Vietnam Invasive Fungal Infection Market Key Takeaways: The Vietnam Invasive Fungal Infection (IFI) market is experiencing significant growth propelled by factors such as an increasing incidence of ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today on ...

Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company ...

Background: Invasive candidiasis is increasingly prevalent in premature infants and seriously ill children, and pediatric data on available antifungal therapies are lacking. Methods: We conducted ...

Fosravuconazole is under clinical development by Eisai and currently in Phase III for Fungal Infections. According to GlobalData, Phase III drugs for Fungal Infections have a 53% phase transition ...

EsoCap AG, the Swiss biotech company dedicated to improving the lives of patients with serious diseases of the upper gastrointestinal tract, announced today that the complete results of the ACESO ...

Fosmanogepix is under clinical development by Basilea Pharmaceutica and currently in Phase II for Candidiasis. According to GlobalData, Phase II drugs for Candidiasis have a 64% phase transition ...